Hartmann, James

Kleine-Levin Syndrome (KLS) is an extremely rare neurological disorder characterized by episodes of uncontrollable hypersomnia and various cognitive and behavioral abnormalities. There is neither a definitive etiology nor definite treatment modalities. Immunological studies for this condition are extremely limited, and this present study aims to investigate a potential autoimmune mechanism that underlies KLS. To achieve this, western blot and dot-blot assays analyzed the immunoreactivity of patients and control sera towards various brain tissue areas. Western blot did not show immunoreactivity with IgG-depleted brain tissue lysate. However, dot-blot assays revealed a significantly greater level of immunoreactivity with KLS patient sera towards the dorsolateral prefrontal cortex, hypothalamus, and parieto-temporal areas compared to KLS-negative sera. These areas have previously been shown to be hypo-perfused in KLS patients. Future studies are necessary to identify the specific antibodies that may be autoreactive in KLS patients.

Prostate cancer, the most frequent non-skin cancer, is the second leading cause of cancer-related deaths in males within the United States. Men diagnosed with metastatic prostate cancer have a 5-year survival rate of approximately 30%. Goals of this study were to produce a combination of compounds that are effective against the disease with minimal side effects on normal cells, especially those of the immune system.
This study showed KBU2046 in combination with calcitriol, limit proliferation, inhibit migration, and are cytotoxic in a testosterone dependent human prostate cancer cell line. Organic compounds, ellagic acid and curcumin were tested alone and in combination with either calcitriol or KBU2046. No combinations were as effective as KBU2046 and calcitriol in inhibiting migration and proliferation of LNCaP cells.
The findings of this study support further investigation into therapeutic use of a combination of KBU2046 and calcitriol in prevention and remission of human prostate cancer.